OMER Ray Aspiri buys $229K worth of shares
Jan 02, 2026, 11:37 AM
0.00%
What does OMER do
Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
Ray Aspiri bought 40,000 shares of OMER on 4 January at $5.72 per share, worth a total of $229K. They now own 186,872 OMER shares, or a 27% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.